Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase IV Clinical Study

Next Previous
X
Search
Trial Profile

Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase IV Clinical Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enterovirus A vaccine (Primary)
  • Indications Enterovirus A infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Nov 2019 Primary endpoint (The effectiveness of inactivated EV71 vaccine in preventing hand-foot-and-mouth disease (HFMD) caused by Enterovirus 71 (EV71) in large scale population of Chinese children (from 6 to 35 months old) in Hubei Province, China) has been met as per the results published in the Clinical Infectious Diseases
    • 18 Nov 2019 Results assessing efficacy and safety of enterovirus 71 vaccine in children aged 6-71 months published in the Clinical Infectious Diseases
    • 26 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top